They said they still need to do dose ranging studies on the drug. I don't see how they'll start the combo study in Q4 if this has to be completed first. Perhaps they will just hurry along with a low dose study. I wonder if they have even done invitro tests with this compound and telaprevir.
In descending order of relevance, the three drugs are: i) ALS-2200 (a/k/a VX-135), the pyrimidine nuke acquired from Alios; ii) Incivek; and iii) VX-222, the non-nuke acquired from ViroChem that doesn’t work too well.
Market Data 
Markets 
AI
